구독하기
연구 모델
서비스
전임상 효능 평가
Resource
huOPA1-del(c.2708-2711) Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
huOPA1-del(c.2708-2711) Mouse
제품명
huOPA1-del(c.2708-2711) Mouse
제품 ID
C001933
품종 계통
C57BL/6JCya-Opa1tm1(hOPA1 c.2708_2711del TTAG)/Cya
Backgroud
C57BL/6JCya
상태
이 마우스 계통을 논문에서 사용할 경우, “huOPA1-del(c.2708-2711) Mouse (카탈로그 번호 C001933)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
HUGO-GT Humanized Models
Disease Animal Models
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
HUGO-GT Humanized Models
Disease Animal Models
기본 정보
관련 자료
기본 정보
유전자명
유전자 별칭
NPG, NTG, MGM1, BERHS, largeG, MTDPS14
NCBI ID
염색체
Chr 3
MGI ID
Datasheet
품종 계통 설명
The OPA1 gene (Mitochondrial Dynamin Like GTPase) is a nuclear-encoded gene that is ubiquitously expressed in human tissues, with particularly high levels in the retina (specifically retinal ganglion cells), brain, heart, and skeletal muscle. It encodes a large dynamin-related GTPase protein that exists as eight distinct isoforms due to alternative splicing; these are further processed into membrane-anchored long forms (L-OPA1) and soluble short forms (S-OPA1) [1]. This protein localizes to the inner mitochondrial membrane and the intermembrane space, where it plays a critical functional role in mediating mitochondrial fusion, maintaining the structural integrity of cristae, and regulating cytochrome c sequestration to prevent apoptosis [2]. Mutations in OPA1 are primarily associated with Autosomal Dominant Optic Atrophy (ADOA), the most common form of hereditary optic neuropathy characterized by the progressive degeneration of retinal ganglion cells and blindness, as well as more severe "ADOA-plus" syndromes and Behr syndrome, which include multisystemic symptoms such as sensorineural deafness, ataxia, peripheral neuropathy, and chronic progressive external ophthalmoplegia (CPEO) [3-4]. The c.2708_2711del mutation is one of the most frequently reported causes of Autosomal Dominant Optic Atrophy (ADOA) worldwide.
The huOPA1-del(c.2708-2711) mouse is a humanized model with a c.2708_2711del TTAG mutation. In this model, the sequence from upstream of exon 1 to downstream of 3’UTR of the mouse Opa1 was replaced with the sequence from upstream of exon 1 to downstream of 3’UTR of the human OPA1. Specifically, the c.2708_2711del TTAG mutation is introduced into exon 27 of the human OPA1 gene. This model is suitable for the study of Autosomal Dominant Optic Atrophy (ADOA), as well as for the development of OPA1-targeted therapies.
Reference
Lee H, Lee TJ, Galloway CA, Zhi W, Xiao W, de Mesy Bentley KL, Sharma A, Teng Y, Sesaki H, Yoon Y. The mitochondrial fusion protein OPA1 is dispensable in the liver and its absence induces mitohormesis to protect liver from drug-induced injury. Nat Commun. 2023 Oct 23;14(1):6721.
Zhang D, Zhang Y, Ma J, Zhu C, Niu T, Chen W, Pang X, Zhai Y, Sun F. Cryo-EM structures of S-OPA1 reveal its interactions with membrane and changes upon nucleotide binding. Elife. 2020 Mar 31;9:e50294.
Yao SQ, Liang JJ, Zhou H, Tan S, Cao Y, Chen CB, Xu C, Wang R, Li TP, Zhao FF, Wang Y, He HJ, Zhang D, Wang M, Liu L, Yu-Wai-Man P, Wei S, Cen LP. Contrasting pathophysiological mechanisms of OPA1 mutations in autosomal dominant optic atrophy. Cell Death Discov. 2025 May 30;11(1):259.
Jagadish S, Calhoun ARUL, Ganganna ST. Recurrent super-refractory status epilepticus and stroke like episode in a patient with Behr syndrome secondary to biallelic variants in OPA1 gene. Epilepsy Behav Rep. 2024 Feb 6;25:100652.
변형 전략
The sequence from upstream of exon 1 to downstream of 3’UTR of the mouse Opa1 was replaced with the sequence from upstream of exon 1 to downstream of 3’UTR of the human OPA1. The c.2708_2711del TTAG point mutation was introduced into exon 27 of the human OPA1 gene. The human EEF1A1P23 and OPA1-AS1 will be expressed in human genomic DNA.

Figure 1. Gene editing strategy of huOPA1-del(c.2708-2711) mice.
응용 분야
Screening, development, and evaluation of OPA1-targeted drugs;
Research on the pathological mechanism and treatment methods of autosomal dominant optic atrophy (ADOA).
관련 자료
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
